A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia

Inclusion Criteria: * Participants with symptomatic syndrome of inappropriate antidiuretic hormone secretion (SIADH) with chronic hyponatremia Exclusion Criteria: * Presence of clinical signs of hypovolemia (e.g. orthostatic decreases in blood pressure and increase in pulse rate, dry mucus membranes, decreased skin turgor) * Presence of clinical signs of hypervolemia (e.g. generalized edema, jugular venous extension) * Participants with adrenocortical insufficiency * Participants with hypothyroidism * Participants with known causes of transient SIADH * Participants with psychogenic polydipsia or beer potomania * Concomitant use of thiazide diuretics during the study * Presence of uncontrolled diabetes with fasting blood glucose ≥200 mg/dL (≥11.09 mmol/L) at time of screening * Participants with impaired hepatic function or liver cirrhosis (Child-Pugh A-C) * Pregnant or breast-feeding women The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.